Health
Daily Pill Shows Tumour Shrinkage in Majority of Advanced Pancreatic Cancer Trial
By Today News Hours Editorial Desk

A daily pill combined with chemotherapy has led to tumour shrinkage or disappearance in over 60% of patients with advanced pancreatic cancer in early trials. In the study, 90% of participants experienced halted tumour growth, and about one in twelve had tumours become undetectable on CT scans. The drug, daraxonrasib, a KRAS inhibitor already approved in the United States, targets RAS mutations that drive tumour growth. Dr. Wungki Park of Memorial Sloan Kettering Cancer Center noted that the treatment produced higher tumour response rates, deeper responses, and nearly doubled disease‑control duration, which may translate into longer survival. Cancer Research UK’s Dr. Sam Godfrey described the results as “the biggest leap forward in decades” and highlighted the potential for the drug to benefit other cancers with similar mutations. The trial followed patients for an average of 18 months; some did not see cancer return during that period, but longer studies are needed to determine if remission can be sustained. Pancreatic cancer remains the cancer with the lowest survival rate in the UK, with most patients with advanced disease surviving only months. The disease accounts for 11,500 diagnoses and 10,200 deaths annually in Britain. Symptoms include jaundice, itchy skin, darker urine, paler stools, unexplained weight loss, fatigue, and fever.